دورية أكاديمية
COVID-19 therapeutics: Challenges and directions for the future.
| العنوان: | COVID-19 therapeutics: Challenges and directions for the future. |
|---|---|
| المؤلفون: | Robinson PC; Faculty of Medicine, University of Queensland School of Clinical Medicine, Herson, QLD 4006, Australia.; Metro North Hospital & Health Service, Royal Brisbane & Women's Hospital, Herston, QLD 4029, Australia., Liew DFL; Department of Medicine, University of Melbourne, Melbourne, VIC 3010, Australia.; Department of Rheumatology, Austin Health, Melbourne, VIC 3084, Australia.; Department of Clinical Pharmacology and Therapeutics, Austin Health, Melbourne, VIC 3084, Australia., Tanner HL; Faculty of Medicine, University of Queensland School of Clinical Medicine, Herson, QLD 4006, Australia.; Metro North Hospital & Health Service, Royal Brisbane & Women's Hospital, Herston, QLD 4029, Australia., Grainger JR; Lydia Becker Institute of Immunology and Inflammation, The University of Manchester, Manchester M13 9PL, United Kingdom., Dwek RA; Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford OX1 2JD, United Kingdom., Reisler RB; Medical Division, Davis Defense Group, Stafford, VA 22554., Steinman L; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305.; Department of Pediatrics, Stanford University, Stanford, CA 94305., Feldmann M; Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom., Ho LP; Medical Research Council Human Immunology Unit, University of Oxford, Oxford OX3 7LD, United Kingdom., Hussell T; Lydia Becker Institute of Immunology and Inflammation, The University of Manchester, Manchester M13 9PL, United Kingdom., Moss P; College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom., Richards D; Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, United Kingdom., Zitzmann N; Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford, Oxford OX1 2JD, United Kingdom. |
| المصدر: | Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2022 Apr 12; Vol. 119 (15), pp. e2119893119. Date of Electronic Publication: 2022 Apr 06. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Washington, DC : National Academy of Sciences |
| مواضيع طبية MeSH: | Pandemics*/prevention & control , COVID-19 Drug Treatment*, COVID-19 Vaccines ; Drug Development ; Humans ; SARS-CoV-2 |
| مستخلص: | The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the greatest medical emergency of the last century. COVID-19 has highlighted health disparities both within and between countries and will leave a lasting impact on global society. Nonetheless, substantial investment in life sciences over recent decades has facilitated a rapid scientific response with innovations in viral characterization, testing, and sequencing. Perhaps most remarkably, this permitted the development of highly effective vaccines, which are being distributed globally at unprecedented speed. In contrast, drug treatments for the established disease have delivered limited benefits so far. Innovative and rapid approaches in the design and execution of large-scale clinical trials and repurposing of existing drugs have saved many lives; however, many more remain at risk. In this review we describe challenges and unmet needs, discuss existing therapeutics, and address future opportunities. Consideration is given to factors that have hindered drug development in order to support planning for the next pandemic challenge and to allow rapid and cost-effective development of new therapeutics with equitable delivery. |
| References: | Lancet. 2021 Sep 4;398(10303):843-855. (PMID: 34388395) N Engl J Med. 2021 Aug 26;385(9):777-789. (PMID: 34351722) Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. (PMID: 32350134) Viruses. 2021 Apr 30;13(5):. (PMID: 33946304) Lancet Rheumatol. 2020 Nov;2(11):e653-e655. (PMID: 33521660) J Infect Dis. 2021 Jul 15;224(Supplement_1):S1-S21. (PMID: 34111271) N Engl J Med. 2021 Apr 22;384(16):1491-1502. (PMID: 33631065) Drug Saf. 2008;31(11):965-88. (PMID: 18840017) N Engl J Med. 2021 Feb 25;384(8):693-704. (PMID: 32678530) Nature. 2021 Jul;595(7866):283-288. (PMID: 34010947) N Engl J Med. 2021 Feb 11;384(6):497-511. (PMID: 33264556) J Thromb Haemost. 2021 Feb;19(2):574-581. (PMID: 33217134) Lancet Respir Med. 2020 Nov;8(11):1106-1120. (PMID: 32979987) PLoS Pathog. 2021 Jul 19;17(7):e1009766. (PMID: 34280244) Med (N Y). 2020 Dec 18;1(1):90-102. (PMID: 33294881) Antiviral Res. 2021 Apr;188:105033. (PMID: 33549572) JAMA Netw Open. 2021 Oct 1;4(10):e2129639. (PMID: 34661663) Intern Emerg Med. 2020 Aug;15(5):861-863. (PMID: 32557383) Ann Neurol. 2014 Sep;76(3):393-402. (PMID: 25043598) Gut. 2021 Apr;70(4):725-732. (PMID: 33082265) Lancet Haematol. 2020 Aug;7(8):e575-e582. (PMID: 32619411) Nat Rev Immunol. 2013 Jan;13(1):34-45. (PMID: 23222502) Clin Infect Dis. 2021 Oct 5;73(7):e1762-e1765. (PMID: 32986807) Nat Rev Drug Discov. 2021 May;20(5):329-331. (PMID: 33879882) Nat Med. 2021 May;27(5):904-916. (PMID: 33879890) Lancet. 2021 May 01;397(10285):1637-1645. (PMID: 33933206) N Engl J Med. 2021 Jan 21;384(3):229-237. (PMID: 33113295) Ann Intern Med. 2021 Nov;174(11):1572-1585. (PMID: 34461029) Lancet Respir Med. 2021 Jul;9(7):763-772. (PMID: 33844996) Radiology. 2021 Oct;301(1):E353-E360. (PMID: 34032513) Ann Rheum Dis. 2020 Oct;79(10):1386-1388. (PMID: 32381561) J Allergy Clin Immunol. 2020 Jul;146(1):119-127.e4. (PMID: 32360286) N Engl J Med. 2020 Jul 9;383(2):120-128. (PMID: 32437596) Nat Rev Drug Discov. 2017 Dec 28;17(1):78. (PMID: 29282366) Med (N Y). 2020 Dec 18;1(1):128-138.e3. (PMID: 32838352) J Thromb Haemost. 2020 Jul;18(7):1743-1746. (PMID: 32320517) Sci Immunol. 2020 Sep 17;5(51):. (PMID: 32943497) Nat Med. 2021 Jul;27(7):1178-1186. (PMID: 33953384) Lancet. 2020 May 2;395(10234):1407-1409. (PMID: 32278362) Lancet. 2021 Jul 10;398(10295):101-103. (PMID: 33991477) Clin Infect Dis. 2020 Jul 28;71(15):762-768. (PMID: 32161940) N Engl J Med. 2022 Feb 10;386(6):509-520. (PMID: 34914868) Science. 2020 Oct 23;370(6515):. (PMID: 32972995) Ann Rheum Dis. 2021 Jul;80(7):943-951. (PMID: 33478953) J Allergy Clin Immunol. 2021 Feb;147(2):510-519.e5. (PMID: 33068560) J Med Chem. 2020 Apr 23;63(8):4205-4214. (PMID: 32227946) Lancet Respir Med. 2022 Mar;10(3):255-266. (PMID: 34922649) Emerg Microbes Infect. 2020 Dec;9(1):761-770. (PMID: 32228226) Lancet. 2021 Mar 20;397(10279):1063-1074. (PMID: 33676597) Lancet. 2021 Jan 16;397(10270):220-232. (PMID: 33428867) JAMA. 2020 Oct 6;324(13):1307-1316. (PMID: 32876695) Nature. 2021 Jun;594(7862):259-264. (PMID: 33887749) Proc Natl Acad Sci U S A. 2020 Oct 6;117(40):24620-24626. (PMID: 32883878) Immunity. 2020 Dec 15;53(6):1296-1314.e9. (PMID: 33296687) JAMA. 2022 Feb 1;327(5):427-429. (PMID: 35029644) JAMA. 2020 Oct 6;324(13):1317-1329. (PMID: 32876697) JAMA. 2020 Oct 6;324(13):1330-1341. (PMID: 32876694) JAMA. 2021 Feb 16;325(7):632-644. (PMID: 33475701) Front Med (Lausanne). 2020 Sep 09;7:539. (PMID: 33072773) Lancet Respir Med. 2021 Aug;9(8):924-932. (PMID: 34051877) N Engl J Med. 2021 Nov 18;385(21):1941-1950. (PMID: 34706189) N Engl J Med. 2021 Jul 29;385(5):406-415. (PMID: 34133856) Ann Intern Med. 2020 Aug 18;173(4):268-277. (PMID: 32374815) J Pathol. 2004 Jun;203(2):631-7. (PMID: 15141377) PLoS One. 2010 Dec 07;5(12):e15004. (PMID: 21165148) Gastroenterology. 2020 Aug;159(2):481-491.e3. (PMID: 32425234) Ann Rheum Dis. 2021 Oct;80(10):1330-1338. (PMID: 34127481) J Clin Invest. 2020 Nov 2;130(11):6151-6157. (PMID: 32759504) J Clin Transl Sci. 2021 Jun 25;5(1):e146. (PMID: 34457357) Science. 2020 Oct 23;370(6515):. (PMID: 32972996) Science. 2020 Sep 4;369(6508):. (PMID: 32669297) Lancet Respir Med. 2020 Nov;8(11):1154-1158. (PMID: 33131609) N Engl J Med. 2021 Mar 4;384(9):795-807. (PMID: 33306283) Intensive Care Med. 2020 Jun;46(6):1089-1098. (PMID: 32367170) Sci Rep. 2020 Dec 10;10(1):21697. (PMID: 33303843) Mol Med. 2020 Oct 29;26(1):97. (PMID: 33121429) Immunity. 2021 Jun 8;54(6):1257-1275.e8. (PMID: 34051148) Nature. 2020 Aug;584(7821):430-436. (PMID: 32640463) JAMA. 2021 May 18;325(19):2015-2016. (PMID: 33825846) Nat Med. 2020 Oct;26(10):1623-1635. (PMID: 32807934) N Engl J Med. 2021 Jan 21;384(3):238-251. (PMID: 33332778) Epidemiol Infect. 2021 Jan 19;149:e32. (PMID: 33461632) Am J Phys Med Rehabil. 2021 Jun 1;100(6):533-538. (PMID: 33901039) Lancet Respir Med. 2020 Jul;8(7):681-686. (PMID: 32473124) Lancet Rheumatol. 2022 Jan;4(1):e3-e5. (PMID: 34806035) Ann Am Thorac Soc. 2020 Jul;17(7):879-891. (PMID: 32267771) Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264) JAMA. 2000 Feb 23;283(8):1016-24. (PMID: 10697061) mSphere. 2020 Aug 12;5(4):. (PMID: 32817460) Ann Rheum Dis. 2020 Jul;79(7):859-866. (PMID: 32471903) Lancet. 2020 Feb 15;395(10223):473-475. (PMID: 32043983) Nature. 2008 Feb 28;451(7182):1076-81. (PMID: 18278032) JCI Insight. 2020 Jun 4;5(11):. (PMID: 32329756) Blood Rev. 2021 Mar;46:100743. (PMID: 32829962) Lancet. 2021 Jun 12;397(10291):2253-2263. (PMID: 34097856) N Engl J Med. 2021 Oct 7;385(15):1382-1392. (PMID: 34260849) N Engl J Med. 2021 Mar 11;384(10):905-914. (PMID: 33356051) Curr Opin Struct Biol. 2016 Feb;36:122-32. (PMID: 26919170) Free Neuropathol. 2021 Jan 18;2:. (PMID: 33554218) Biochem Soc Trans. 2020 Jun 30;48(3):1287-1295. (PMID: 32510142) N Engl J Med. 2020 Nov 5;383(19):1813-1826. (PMID: 32445440) Mol Ther Nucleic Acids. 2014 Oct 07;3:e201. (PMID: 25291143) Circulation. 2020 Sep 22;142(12):1176-1189. (PMID: 32755393) Med (N Y). 2021 May 14;2(5):493-497. (PMID: 33899041) Ann Intern Med. 2021 Sep;174(9):1334-1336. (PMID: 34029484) EMBO Mol Med. 2021 Jan 11;13(1):e13426. (PMID: 33179852) J Med Virol. 2022 Jan;94(1):161-172. (PMID: 34415583) Wellcome Open Res. 2021 Feb 22;6:38. (PMID: 33997298) JAMA Netw Open. 2021 Feb 1;4(2):e210830. (PMID: 33606031) Lancet Respir Med. 2021 Feb;9(2):196-206. (PMID: 33189161) Nat Med. 2020 Oct;26(10):1636-1643. (PMID: 32839624) Nature. 2021 Jul;595(7868):565-571. (PMID: 34153974) Ann Rheum Dis. 2021 Jul;80(7):930-942. (PMID: 33504483) |
| فهرسة مساهمة: | Keywords: epidemiology; immunology; virology |
| المشرفين على المادة: | 0 (COVID-19 Vaccines) |
| تواريخ الأحداث: | Date Created: 20220406 Date Completed: 20220415 Latest Revision: 20221207 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC9169797 |
| DOI: | 10.1073/pnas.2119893119 |
| PMID: | 35385354 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1091-6490 |
|---|---|
| DOI: | 10.1073/pnas.2119893119 |